Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03160079
Title Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Matthew Wieduwilt, M.D., Ph.D.

acute lymphoblastic leukemia


Blinatumomab + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.